전이성 유방암 환자의 항암화학요법; Paclitaxel (Genexol)의 치료 효과

Background : Metastatic breast cancer is a systemic disease, and the therapeutic goal is the palliation or cure of the disease. In recent, good results have been reported in the treatment of metastatic breast cancer by using single-agent paclitaxel chemotherapy. Methods : This retrospective study was performed a by analyzing the medical records of patients treated at Kosin University Gospel Hospital between August 2001 and June 2002. Total 37 patients with metastatic breast cancer were treated by 175mg/m2, 3-hour infusion of paclitaxel every 3 weeks. The results were reviewed with respect to the response rates and toxicities of paclitaxel. Results : The overall response rate was 13.5%" Complete response rate of 2.7% (1 out of 37) and Partial response rate of 10.8% (4 out of 37). The most common toxicity was alopecia and myalgia and dangerous grade IV was pancytopenia was occurred in one patient. However, the patients were tolerated this therapy. Conclusion : Paclitaxel as a single-agent therapy with low dose, short time injection was tolerable and effective for metastatic breast cancer. KCI Citation Count: 0